A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Trial Profile

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Alisertib (Primary) ; Gemcitabine; Pralatrexate; Romidepsin
  • Indications Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms LUMIERE
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 25 Apr 2018 This trial has been completed in Hungary (2017-12-18) , according to European Clinical Trials Database
    • 24 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 25 Oct 2017 This study is completed in Denmark (EudraCT2011-003545-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top